DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

At DBV Technologies, we are committed to improving the lives of people who suffer from food allergies. By developing innovative immunotherapy treatments that target the underlying causes of these conditions, we strive to create lasting improvements in the lives of our patients.

Our vision is to become the global leader in food allergy prevention and treatment, and to provide the highest quality care to our patients.

Since its founding, DBV Technologies has been recognized for its commitment to excellence and innovation, receiving numerous awards, including the Goldman Sachs 10,000 Small Businesses Award and the BioPharma Deal of the Year Award.